Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. - Wikidata - wikimedia - TriplyDB

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

http://www.wikidata.org/entity/Q35223241

about

Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Genetically modified T cells in cancer therapy: opportunities and challenges Lineage relationship of effector and memory T cells Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Designing chimeric antigen receptors to effectively and safely target tumors Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.In Vivo Murine-Matured Human CD3+ Cells as a Preclinical Model for T Cell-Based Immunotherapies.The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy Host STAT2/type I interferon axis controls tumor growth.Expansion of melanoma-specific lymphocytes in alternate gamma chain cytokines: gene expression variances between T cells and T-cell subsets exposed to IL-2 versus IL-7/15 Clinical application of genetically modified T cells in cancer therapy.Neem leaf glycoprotein activates CD8(+) T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity.Genetically engineered T cells for the treatment of cancer.Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy.The past, present, and future of adoptive T cell therapy.Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.Clinical opportunities in combining immunotherapy with radiation therapy.Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model.New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma

P2860

Q26767514-897F8EF9-5222-4939-96F6-CEA80C2D3A99 Q26774669-20882D7B-F3F5-470C-AF67-B89CF194F51C Q27002575-4B18977D-A635-416A-BC12-383239DB5471 Q27004178-12B0DB16-6C57-4B1D-BE0F-253859387FC2 Q27026627-B9EFBB01-3471-4057-960C-D702A384DA09 Q27026665-610658D1-60D9-47D9-A09E-FB7CD68D60EC Q27314843-73635C5E-9BAB-40BB-899F-0346F726293F Q27334215-66CB474B-3E3B-482B-8EDA-CF1BF85FDA96 Q28068378-51DA0B6E-446F-476A-8B6F-B5C8CDE4FD38 Q28088526-66E7EC82-68AF-4095-981F-1CD735DD38BB Q30399332-C01D8A7A-9D81-4F90-B28B-D911BB97047F Q33587034-4D2C8599-DB8F-4BB8-A993-0D98BBD67D88 Q33796950-4AC47F5F-CDC1-4AE1-90F6-8C18C3D7827F Q33928765-223A62C9-A033-456F-B85A-580A1AF14E29 Q34270375-31A86DE3-28D9-4B11-854F-9F885C8416F7 Q34334598-69E55D68-2D34-4E34-A9C6-DBBD79CADAA3 Q34353298-43775A1F-4D8C-43D5-8592-E6A2555AD6B0 Q34381488-7B00AD42-16B5-4551-9903-20B46EB4C121 Q34511646-E7510CBE-DADC-419E-B1D9-DF2177D9F4D2 Q34550822-7E5F1D19-3362-424E-B7C3-8683A691427A Q34560345-75DA01B9-3A0E-48DA-879B-652CBD4CE0CB Q34645898-C30D6D57-0400-46EC-8A7F-7321BCF07F4A Q34823085-10BE92B4-DD6B-4D82-9AD4-40CB08CC3281 Q35130794-F60FC5C2-DD94-4E3B-94E6-B3D7B8F25A58 Q35145392-ECEA6A36-E45F-47E8-BA78-7609B6C6AE7B Q35257907-159C3F98-753C-4A39-A921-E416298DC0C2 Q35568556-28EEEA4C-D3CA-454B-B6D1-E41A135F5376 Q35585735-9F752956-E1E7-4588-9682-698A36F71A61 Q35811921-B5D88956-CD27-4900-B3DB-A676991374B9 Q35979037-78B564C4-5ED6-492F-8C9D-5BFF276ABF9A Q35980893-9F3CFFDF-FD21-482F-9E1A-10A1E6C86A9B Q36043637-80FFD8AE-EE04-4315-BDA9-B47E16FDBBD7 Q36306644-95016EED-8AB6-40D3-B231-AE7449A2D8DE Q36430680-6577B6BA-0160-4EFC-BED8-111D7107D757 Q36449873-C6FF1F7A-EB96-428B-BD45-AC1A2A737FBA Q36475411-D5D31FC9-F3E1-451B-86AF-8C43D4B5FD99 Q36487567-D939BC09-FC0F-4636-B9FD-D14BD1D16084 Q36487595-B1A425D9-96D0-4700-BBA9-CB879EEF12C1 Q36558375-A2395008-A8DA-45CF-853C-C35DA9E2D988 Q36618229-1CE5B0D2-6BCF-4E9E-9934-EB0F5ED99779

P2860

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

http://www.wikidata.org/entity/Q35223241

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Determinants of successful CD8 ...... ge established tumors in mice.

@ast

Determinants of successful CD8 ...... ge established tumors in mice.

@en

type

label

Determinants of successful CD8 ...... ge established tumors in mice.

@ast

Determinants of successful CD8 ...... ge established tumors in mice.

@en

prefLabel

Determinants of successful CD8 ...... ge established tumors in mice.

@ast

Determinants of successful CD8 ...... ge established tumors in mice.

@en

P1433

Q35223241-6BD03A1E-F57F-4BEF-A80F-700B7B7077CC

P1476

Q35223241-9D08C35E-2585-4A30-9327-1E3880A0AF5B

P2093

Q35223241-11416597-8434-4E65-8D4B-A8AEA577678A

Q35223241-31E3049E-ACD1-47C6-9FB2-A79819109244

Q35223241-4EF4B768-B3BD-40C5-B839-DD9961E8C05A

Q35223241-56AE9DBD-0458-4790-92D4-5DDEDFE6B3C1

Q35223241-688DF638-26FE-4FFB-85B8-9696226CE716

Q35223241-750250A7-7857-4C9D-B532-55F6AEFD4E7A

Q35223241-9ACC70C6-2024-4DEB-BD10-1A8BC10344EA

Q35223241-E3949F57-6594-4105-850C-F45D7359AE15

Q35223241-E7D0C9BC-93C6-4483-9B62-DF6481556E39

Q35223241-F2F6CFF4-2097-453B-A42D-1DEA2A1FF1CC

P2860

Q35223241-0A106B1A-0D64-47FF-933F-0B2EBC3D879D

Q35223241-0B41F722-5090-484D-8D61-1F03B5680535

Q35223241-0F69D57D-E5E5-4782-A340-F88D7626DCDC

Q35223241-1379D783-A7DE-4F6A-87F9-D7C4135F1BE4

Q35223241-14466AFA-B7CE-4E5C-9DD1-9E0471B59B71

Q35223241-198F1C7A-8048-44D3-9183-9F77C1E454A7

Q35223241-22DB93F1-DD4D-4753-916D-8408020AB38F

Q35223241-2AEBC565-35B7-4CCF-8517-012499B1231F

Q35223241-2BE3396B-A95F-4C2E-BF14-5A6AAE23D37F

Q35223241-2C4B2EBC-2781-4672-9532-B04D9180B495

P304

Q35223241-EA059D0F-A4EC-447B-9BBA-1F893B85115C

P31

Q35223241-3341944B-C3B5-459F-84E2-A44DB6B13CE2

P356

Q35223241-5B80B0F2-2ABD-4674-A79A-8EFB7D00F9AD

P407

Q35223241-E6713DEE-3508-4BE0-8EDD-3E4D0B3F5311

P433

Q35223241-010DCD48-6BD2-4B6F-8427-CFB68F3A7C1C

P478

Q35223241-95486655-B32F-4EF2-B4B2-4FCDE091FC0A

P50

Q35223241-06E6F99F-540A-4B48-8720-B6D2E6A85BF7

P577

Q35223241-EB81F21B-2429-4ADB-9214-13FDE6823B76

P698

Q35223241-7F150F5A-613C-4E7F-9AFE-1A5DBC4241DE

P921

Q35223241-70B0A821-59C7-4266-9B56-DB7832485D72

P932

Q35223241-E50D5EED-95CC-41E4-AAE8-3A34C8A893E8

P356

1078-0432.CCR-11-0503

P1433

Clinical Cancer Research

P1476

Determinants of successful CD8 ...... ge established tumors in mice.

@en

P2093

Christian S Hinrichs

http://www.w3.org/2001/XMLSchema#string

Christopher A Klebanoff

http://www.w3.org/2001/XMLSchema#string

Christopher D Scott

http://www.w3.org/2001/XMLSchema#string

Luca Gattinoni

http://www.w3.org/2001/XMLSchema#string

Nicholas P Restifo

http://www.w3.org/2001/XMLSchema#string

Pawel Muranski

http://www.w3.org/2001/XMLSchema#string

Sid P Kerkar

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

Steven E Finkelstein

http://www.w3.org/2001/XMLSchema#string

Yun Ji

http://www.w3.org/2001/XMLSchema#string

P2860

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

Cancer regression in patients after transfer of genetically engineered lymphocytes

P304

5343-5352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-0503

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21737507

http://www.w3.org/2001/XMLSchema#string

P921

P932

3176721

http://www.w3.org/2001/XMLSchema#string